Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ: SYRS) has announced significant advancements in its clinical programs. The company initiated an expansion cohort for SY-5609 combined with chemotherapy for pancreatic cancer patients, with results expected in late 2022. Additionally, a Phase 1 trial for SY-5609 in hematologic malignancies is set to begin in the second half of 2022, alongside the nomination of a new development candidate from the CDK12 program. Syros remains optimistic about three key clinical data readouts in 2022 and is in a strong financial position to support operations into 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in fireside chats at two virtual investor conferences. The Piper Sandler 33rd Annual Healthcare Conference will take place on November 23, 2021, with a pre-recorded chat available on-demand at 10:00 a.m. ET. The JMP Securities Hematology and Oncology Summit is scheduled for December 6, 2021, at 10:40 a.m. ET. Webcasts and archived recordings can be accessed on Syros' website. The company is focused on developing gene expression medicines and has a robust clinical pipeline.
Syros Pharmaceuticals (NASDAQ:SYRS) announced significant progress in its clinical trials, including the dosing of the first patient in the SELECT-AML-1 Phase 2 trial of tamibarotene and the dose confirmation study of SY-2101 in acute promyelocytic leukemia (APL). Financial results for Q3 2021 revealed revenues of $5.7 million, up from $3.8 million in Q3 2020, though the company reported a net loss of $26 million. Notably, SY-5609 showed clinical activity in difficult-to-treat tumors during a recent Phase 1 trial. The company expects existing funds to sustain operations into 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a conference call on November 5, 2021, at 8:30 a.m. ET, to discuss its third quarter 2021 financial results and corporate updates. Interested parties can join the call by dialing (866) 595-4538 domestically or (636) 812-6496 internationally, referencing conference ID 3287324. A webcast will be available on their website, with an archived replay accessible for 30 days.
Syros focuses on developing gene expression medicines and has a promising clinical pipeline, including treatments for various hematologic malignancies.
Syros Pharmaceuticals (SYRS) announced the grant of a stock option award to Jason Haas, its newly appointed Chief Financial Officer. The Board approved an option to purchase 750,000 shares at an exercise price of $4.54, equivalent to the closing stock price on October 12, 2021. The option has a 10-year term, vesting 25% on the first anniversary of employment, followed by monthly vesting. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a key part of Haas's compensation, aiming to strengthen the company's leadership in gene expression medicines.
Syros Pharmaceuticals (NASDAQ:SYRS) has appointed Jason Haas as Chief Financial Officer, bringing over 25 years of healthcare investment banking experience. CEO Nancy Simonian emphasized Haas's financial, strategic, and leadership expertise, crucial as the company transitions to a commercial-stage entity. Haas previously held senior roles at Barclays, Deutsche Bank, and Goldman Sachs. He expressed excitement about joining Syros during a pivotal time with multiple clinical programs aimed at setting new care standards. The company is focused on delivering innovative gene-controlled therapies.
Syros Pharmaceuticals (NASDAQ:SYRS) has initiated dosing in a confirmatory study for SY-2101, an oral formulation of arsenic trioxide aimed at treating acute promyelocytic leukemia (APL). This study will evaluate pharmacokinetics, safety, and tolerability, laying the groundwork for a planned Phase 3 trial. APL, accounting for about 10% of acute myeloid leukemia cases, has limited treatment options that can be burdensome. Preliminary Phase 1 data for SY-2101 is promising, and the company anticipates filing a New Drug Application by 2024.
Syros Pharmaceuticals (NASDAQ: SYRS) granted an inducement stock option award to its new Chief Commercial Officer, Conley Chee. This award includes options to purchase 360,000 shares at an exercise price of $4.81, aligned with the stock's closing price on September 27, 2021. The options have a 10-year term and will vest over four years, contingent on Mr. Chee's continued employment. This grant aims to attract talent and aligns with Nasdaq Listing Rule 5635(c)(4). Syros is focused on developing innovative gene-expression controlling medicines.
Syros Pharmaceuticals (NASDAQ:SYRS) has appointed Conley Chee as its first Chief Commercial Officer, enhancing its leadership team ahead of critical drug applications expected in 2024. Chee, with 20 years of experience from Novartis, will lead the commercial strategy for the company's late-stage therapies targeting hematologic malignancies. CEO Nancy Simonian emphasized the importance of building a robust commercial organization at this pivotal time. Syros aims to deliver impactful treatments to patients and has a strong pipeline, including drugs for acute myeloid leukemia and blood cancers.
Syros Pharmaceuticals (NASDAQ:SYRS) reported promising new data from the Phase 1 trial of SY-5609, a CDK7 inhibitor, showcasing clinical activity in heavily pre-treated cancer patients. Notably, 28.9% achieved stable disease with tumor regressions, particularly in pancreatic cancer. Syros plans to expand SY-5609's development with trials combining it with chemotherapy and a BTK inhibitor. The company emphasizes a tolerable dosing schedule and supportive preclinical data, aiming for significant opportunities in challenging cancer treatments.
FAQ
What is the current stock price of Syros Pharmaceuticals (SYRS)?
What is the market cap of Syros Pharmaceuticals (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
